USPTO serial 79068397
GEX
Reviewed by CopyMark Law Group
Reg. 3870245Status 707Registered
- Filing date
- Status date
- Registration date
- Nov 2, 2010
- Examiner
- MORRIS, KRISTINA KLOIBER
- Law office
- —
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with GEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh Ann Lindquist
Leigh Ann Lindquist SUGHRUE MION, PLLC2000 Pennsylvania Avenue NW, Suite 9000Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; unprocessed artificial resins; unprocessed plastics; fertilising preparations; fire extinguishing compositions; tempering and soldering chemicals; chemical substances for fermenting and preserving food stuffs; tanning agents for use in the manufacture of leather; adhesives used in industry; bacteria and cell preparations and elements, fragments, fractions and lysates thereof, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment, bacteria and cell preparations for use in expression of engineered or glycosylated proteins and peptides; preparations containing bacteria and cells, except for medical or veterinary purposes, namely, for use in protein production, food manufacturing, scientific research, waste water treatment; biological preparations for laboratories, except for medical or veterinary purposes, namely, for use in bacterial and cell engineering, cultivation, harvesting, protein production; chemical preparations for analysis in laboratories, namely, preparations for protein, peptide, engineered proteins and peptides, glycoproteins, glycosylation, antibody or antigen analysis, preparations comprising antibody reagents used for the detection of antigens; chemical preparations for scientific purposes; chemical reagents except for medical or veterinary purposes and biological reagents in the nature of reagents for use in protein production, bacterial and cell engineering, cultivation and harvesting, probes for detecting and analyzing molecules in protein or nucleotide arrays, except for medical or veterinary purposes; diagnostic preparations, except for medical or veterinary purposes; enzymes, proteins and respective preparations for industrial purposes, namely, engineered proteins, glycosylated proteins, antibodies, enzymes for use in glycosylation, enzyme substrates, proteins used in the manufacture of cosmetics, beverages, food products and food supplements; ferments for chemical purposes, namely, yeast, bacterium, mold, or enzyme, that causes fermentation; in-vitro diagnostics, other than for medical purposes; carbohydrates for use in the manufacture of food and nutraceuticals; cultures of microorganisms and cells and elements, fragments, fractions and lysates thereof, other than for medical or veterinary purposes, namely, cultures of microorganisms and cells other than for medical and veterinary use, microorganism or cell cultures for use in protein production, food manufacturing, scientific research, waste water treatment, cultures of microorganisms or cells for use in expression of glycosylated proteins and peptides; expression systems for proteins and peptides comprising cells, particularly human cells and microorganisms suitable for expressing engineered or glycosylated proteins or peptides, or capable of providing optimized glycosylation; milk ferments for medical research purposes ] | SECTION 71 - CANCELLED | — |
| 005 | [ Pharmaceutical and veterinary preparations for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; sanitary preparations for medical purposes; dietetic foods adapted for medical use; food for babies; medical plasters; materials for medical dressings; materials for dental filling and impression materials for dental purposes; disinfectants for sanitary purposes; preparations for destroying vermin; fungicides, herbicides; adjuvants for medical purposes; Medicines for human and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, [ allergies, cardiovascular diseases, ] infectious diseases, [ neurological diseases, ] gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological preparations for medical purposes; dietetic food adapted for medical purposes; enzyme, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine, and as nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; vaccines; carbohydrates for medical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of microorganisms for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; cultures of human cells for medical or veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; medical drinks for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; microorganisms, cells and preparations containing elements, fragments, fractions and lysates of microorganisms or cells for medical and veterinary purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; biological therapeutics, namely, therapeutics containing cells, microorganisms, proteins, glycoproteins, peptides, glycopeptides or modified or conjugated versions thereof ; milk ferments for pharmaceutical purposes for prophylaxis or treatment of cancer, inflammatory diseases, autoimmune diseases, allergies, cardiovascular diseases, infectious diseases, neurological diseases, gastrointestinal diseases, and for use in wound healing, formation of blood and tissue and reproduction medicine; nutritional additives and nutritional supplement additives for medical purposes for use in foods and dietary supplements for human consumption; nutrients for medical purposes, namely, enzymes, proteins, antibodies, cells, microorganisms as well as fragments, fractions, elements and lysates thereof as nutritional additives; sugar and carbohydrates for medical purposes, namely, therapeutically and prophylactically active sugar and carbohydrates, dietetic sugar and carbohydrates, sugar and carbohydrate replacements ] | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services and research and designer services relating thereto, namely, scientific research, scientific analysis, technology consultation and research, product development and optimization in the field of biotechnology, protein production, glycosylation, optimization of protein, antibody and enzyme activity, [ bacteria ] and cell engineering, cultivation and harvesting; industrial analysis and research services in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [ bacteria ] and cell engineering, cultivation and harvesting; [ design and development of computer hardware and software; ] biological research; services of a [ chemical or ] biological laboratory; [ technical surveys, namely, ] conducting biotechnology surveys, [ pharmacology surveys; ] conducting scientific surveys in the field of biotechnology, [ bacterial and ] cell engineering, protein production, glycosylation; research and development in the field of [ bacteriology, ] cytology, antibody technology, [ chemistry, ] immunology, [ cosmetics of expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, particularly for proteins and peptides; quality control; ] research and development of new products and technologies in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [ bacteria and ] cell engineering, cultivation and harvesting for others; technology and scientific consultancy in the field of biotechnology, protein production, glycosylation, protein, antibody and enzyme activity, [ bacteria and ] cell engineering, cultivation and harvesting; research and development in the field of glycomics, expression systems in the nature of glycosylation of proteins, peptides, antibodies and enzymes, development and improvement of cells, cell lines [ and microorganisms, ] antibody-engineering, optimised biological therapeutics, [ nutraceuticals, and food and nutritional supplements; ] research, quality control, technology consultancy and product development in the field of proteins, antibodies, [ microorganisms ] and cells; research and development in the field of [ microorganisms and ] cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glycotope GmbH
- Other trademarks owned by Glycotope GmbH
- Other trademarks owned by Glycotope GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named GEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 25, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 2, 2022 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 23, 2022 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 23, 2022 | INPC | INVALIDATION PROCESSED | — |
| Jun 30, 2022 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 30, 2021 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Oct 30, 2021 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Oct 28, 2021 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| May 6, 2021 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Jan 20, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 2, 2020 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 8, 2020 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Dec 16, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 16, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 2, 2019 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Dec 13, 2018 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 4, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 1, 2018 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Mar 30, 2018 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Nov 30, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 20, 2017 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Jun 23, 2017 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jun 23, 2017 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jun 20, 2017 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 27, 2017 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Dec 14, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 18, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 11, 2011 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 11, 2011 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 2, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 2, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 17, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 17, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 16, 2010 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jul 15, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 15, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 15, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 15, 2010 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 15, 2010 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 15, 2010 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 15, 2010 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Jul 15, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 15, 2010 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 15, 2010 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 20, 2010 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 19, 2010 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 1, 2010 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Dec 31, 2009 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Dec 28, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 28, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 28, 2009 | ALIE | ASSIGNED TO LIE | — |
| Dec 14, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 10, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 15, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 15, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 13, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 12, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 5, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 5, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 4, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |